Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck (SCCHN): The KEO Trial
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Jun 2018
At a glance
- Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms The KEO Trial
- 19 Jun 2018 Planned initiation date changed from 1 May 2018 to 1 Nov 2018.
- 16 Apr 2018 Planned initiation date changed from 1 Apr 2018 to 1 May 2018.
- 13 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 1 Apr 2018.